On August 29, 2018 Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, reported reported that Peter H. Nielsen, Chief Executive Officer, will present a corporate overview at the upcoming H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 2:10 p.m. ET in New York (Press release, Bio-Path Holdings, AUG 29, 2018, View Source [SID1234529311]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed under "Presentations and Publications" in the Media section of the Company’s website at www.biopathholdings.com.

On August 29, 2018 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported that the company will present at the Baird Global Healthcare Conference in New York on Thursday, September 6, 2018 at 2:35 p.m. ET (Press release, BioCryst Pharmaceuticals, AUG 29, 2018, http://ir.biocryst.com/news-releases/news-release-details/biocryst-pharmaceuticals-present-baird-global-healthcare [SID1234529126]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Links to a live audio webcast and replay of this presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

On August 29, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, reported that management will present company overviews at the following conferences (Press release, Alnylam, AUG 29, 2018, View Source [SID1234529167]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2018 Wells Fargo Securities Healthcare Conference on Wednesday, September 5, 2018 at 10:15 am ET at the Westin Copley Place in Boston
16th Annual Morgan Stanley Global Healthcare Conference onThursday, September 13, 2018 at 12:20 pm ET at the Grand Hyatt in New York City

A live audio webcast of each presentation will be available on the Investors section of the Company’s website, www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after each event.

On August 29, 2018 Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, reported that Michael Mulroy, President and Chief Executive Officer, will participate in a panel discussion at the B. Riley FBR Healthcare Conference at 8:20am ET/5:20 am PT on Tuesday, September 4, 2018 in New York (Press release, , AUG 29, 2018, View Source;date=August+29%2C+2018&title=Asterias+Biotherapeutics%E2%80%99+CEO+Michael+Mulroy+to+Participate+on+Regenerative+Medicine+Therapies+Panel+at+the+B.+Riley+FBR+Healthcare+Conference [SID1234529206]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The discussion will be moderated by George Zavoico, Senior Research Analyst, SVP Equity Research, B. Riley FBR and the other panelists will include senior executives from other regenerative medicine therapies companies.

Mr. Mulroy will be meeting with investors throughout the conference and one-on-one meetings may be scheduled through the B. Riley 1×1 desk or by contacting Michael Polyviou, at 732-933-2754 or [email protected].

On August 29, 2018 Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, reported that senior management will participate in two upcoming healthcare investor conferences (Press release, Bellicum Pharmaceuticals, AUG 29, 2018, View Source [SID1234529127]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Event: Citi’s 13th Annual Biotech Conference
Date: Wednesday, September 5, 2018
Location: Boston, MA

Event: 2018 Wells Fargo Securities Healthcare Conference
Date/Time: Thursday, September 6, 2018 at 10:55 a.m. EDT
Location: Boston, MA

A live webcast of the presentation at Wells Fargo may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.